消渴丸对人血管内皮细胞增殖及一氧化氮产生的影响
摘要
目的：
1.研究消渴丸不同组分对人血管内皮细胞增殖过程的影响；
2.研究消渴丸不同组分对人血管内皮细胞NO产生的影响；
3.研究消渴丸不同组分对人血管内皮细胞eNOS mRNA表达水平的影响。
通过上述研究,探讨消渴丸不同组分对人血管内皮细胞的作用,以期明确消渴丸中药组分和西药组分对人血管内皮细胞的作用,从而进一步完善消渴丸应用的适应证。
方法：
1.应用不同含药血清作用于人脐静脉内皮细胞,使用XTT比色法测定细胞增殖情况；
2.应用不同含药血清作用于人脐静脉内皮细胞,吸取培养液使用Griess法检测总NO产生情况；
3.应用不同含药血清作用于人脐静脉内皮细胞,提取RNA,采用荧光实时定量RT-PCR法检测eNOS mRNA表达水平。
结果：
1.XTT比色法显示消渴丸和消渴丸中药成分对人脐静脉内皮细胞的增殖能力无显著影响；
2.总NO检测法提示消渴丸、消渴丸中药组分和格列本脲均对人脐静脉细胞NO产生有促进作用；
3.荧光实时定量RT-PCR法显示消渴丸(?)组分对人脐静脉内皮细胞eNOS mRNA的表达起促进作用,但没达到显著差异。
结论：
本研究首次发现消渴丸和消渴丸中药组分对人脐静脉内皮细胞的增殖无显著影响；消渴丸、消渴丸中药组分和格列本脲均对人脐静脉内皮细胞NO产生有促进作用；消渴丸中药成分对人脐静脉内皮细胞eNOS mRNA的表达起促进作用,但没达到显著差异。
Objective:
1. To investigate the effects of different parts of the traditional Chinese medicine XiaoKeWan on the proliferation of HUVEC;
2. To investigate the effects of different parts of the traditional Chinese medicine XiaoKeWan on the production of NO of HUVEC;
3. To investigate the effects of different parts of the traditional Chinese medicine XiaoKeWan on eNOS mRNA expression of HUVEC.
This study was aimed at characterizing the response to XiaoKeWan of HUVEC, in terms of proliferation and production of NO, to clarify the function of XiaoKeWan on the endothelial cells and then discuss its therapeutic use from this point.
Methods:
1. HUVECs were cultured in the presence of different parts of the traditional Chinese medicine XiaoKeWan. XTT assay was applied to evaluate the cell growth.
2. HUVECs were cultured in the presence of different parts of the traditional Chinese medicine XiaoKeWan. Then the total NO in the medium was measured with the Griess method.
3. Realtime PCR was applied to measure the levels of eNOS mRNA expressing in the culture of different parts of the traditional Chinese medicine XiaoKeWan.
Results:
1. XiaoKeWan and its Chinese medicine part exhibited no obvious effect on the proliferative activity of HUVEC.
2. XiaoKeWan, the Chinese medicine.part of XiaoKeWan, and glyburide all increased the production of NO.
3. The Chinese medicine part of XiaoKeWan increased the expression of eNOS mRNA, but no significant differences.
Conclusion:
Our study discovered that XiaoKeWan and its Chinese medicine part exhibited no obvious effect on the proliferative activity of HUVEC; XiaoKeWan, the Chinese medicine part of XiaoKeWan, and glyburide all increased the production of NO; the Chinese medicine part of XiaoKeWan increased the expression of eNOS mRNA, but no significant differences.
1.研究消渴丸不同组分对人血管内皮细胞增殖过程的影响；
2.研究消渴丸不同组分对人血管内皮细胞NO产生的影响；
3.研究消渴丸不同组分对人血管内皮细胞eNOS mRNA表达水平的影响。
通过上述研究,探讨消渴丸不同组分对人血管内皮细胞的作用,以期明确消渴丸中药组分和西药组分对人血管内皮细胞的作用,从而进一步完善消渴丸应用的适应证。
方法：
1.应用不同含药血清作用于人脐静脉内皮细胞,使用XTT比色法测定细胞增殖情况；
2.应用不同含药血清作用于人脐静脉内皮细胞,吸取培养液使用Griess法检测总NO产生情况；
3.应用不同含药血清作用于人脐静脉内皮细胞,提取RNA,采用荧光实时定量RT-PCR法检测eNOS mRNA表达水平。
结果：
1.XTT比色法显示消渴丸和消渴丸中药成分对人脐静脉内皮细胞的增殖能力无显著影响；
2.总NO检测法提示消渴丸、消渴丸中药组分和格列本脲均对人脐静脉细胞NO产生有促进作用；
3.荧光实时定量RT-PCR法显示消渴丸(?)组分对人脐静脉内皮细胞eNOS mRNA的表达起促进作用,但没达到显著差异。
结论：
本研究首次发现消渴丸和消渴丸中药组分对人脐静脉内皮细胞的增殖无显著影响；消渴丸、消渴丸中药组分和格列本脲均对人脐静脉内皮细胞NO产生有促进作用；消渴丸中药成分对人脐静脉内皮细胞eNOS mRNA的表达起促进作用,但没达到显著差异。
Objective:
1. To investigate the effects of different parts of the traditional Chinese medicine XiaoKeWan on the proliferation of HUVEC;
2. To investigate the effects of different parts of the traditional Chinese medicine XiaoKeWan on the production of NO of HUVEC;
3. To investigate the effects of different parts of the traditional Chinese medicine XiaoKeWan on eNOS mRNA expression of HUVEC.
This study was aimed at characterizing the response to XiaoKeWan of HUVEC, in terms of proliferation and production of NO, to clarify the function of XiaoKeWan on the endothelial cells and then discuss its therapeutic use from this point.
Methods:
1. HUVECs were cultured in the presence of different parts of the traditional Chinese medicine XiaoKeWan. XTT assay was applied to evaluate the cell growth.
2. HUVECs were cultured in the presence of different parts of the traditional Chinese medicine XiaoKeWan. Then the total NO in the medium was measured with the Griess method.
3. Realtime PCR was applied to measure the levels of eNOS mRNA expressing in the culture of different parts of the traditional Chinese medicine XiaoKeWan.
Results:
1. XiaoKeWan and its Chinese medicine part exhibited no obvious effect on the proliferative activity of HUVEC.
2. XiaoKeWan, the Chinese medicine.part of XiaoKeWan, and glyburide all increased the production of NO.
3. The Chinese medicine part of XiaoKeWan increased the expression of eNOS mRNA, but no significant differences.
Conclusion:
Our study discovered that XiaoKeWan and its Chinese medicine part exhibited no obvious effect on the proliferative activity of HUVEC; XiaoKeWan, the Chinese medicine part of XiaoKeWan, and glyburide all increased the production of NO; the Chinese medicine part of XiaoKeWan increased the expression of eNOS mRNA, but no significant differences.
引文
[1]沈元良糖尿病应用消渴丸的宜与忌[J]实用中医内科学杂志,2008年第22卷第1期：41
[2]江清林,李延军,辛华.黄芪甲甙对胰岛素C肽分泌作用研究[J].黑龙江医药科学,1999,22(3)：24027.
[3]高学敏.中药学[M].北京：人民卫生出版社,2000：388.
[4]丁学屏.中西医结合治疗糖尿病[M].北京：人民卫生出版社,2004：1240143.
[5]沈忠明,李英,姜宏,等.降糖中药对α 0葡萄糖苷酶抑制作用的研究[J].中国生化药物杂志,2000,21(2)：69070.
[6]袁海波,沈忠明,殷建伟,等.五味子中α 0葡萄糖苷酶抑制剂对小鼠的降血糖作用[J].中国生化药物杂志,2002,23(3)：1120114.
[7]于健.葛根素治疗2型糖尿病患者胰岛素抵抗的临床研究[J].山东中医杂志,2001,20(12)：7270729.
[8]袁昌杰.消渴丸治疗90例2型糖尿病疗效观察[J].广东医学,2008,29(12)：210502106.
[9]吴继良.消渴丸治疗糖尿病疗效观察[J].实用中西医结合临床,2005,5(6)：18019.
[10]Potenza MA Gagliardi S Nacci C Carratu' MR Montagnani M Endothelial dysfunction in diabetes:from mechanisms to therapeutic targets Current medicinal chemistry,2009,16 (1):P.94-112
[11]雷世庸,胡娟娟中药血清药理学研究现状[J]现代医药卫生2009年第25卷第13期P2019
[12]王洪武,倪青,林兰中药含药血清的研究进展及其在中医学中的应用[J]北京中医药2008年9月第27卷第9期
[13]洪思佳,万建波,张庆文,张娥,胡光,刘倩青,李铭源一,王一涛三七总皂苷对人脐静脉内皮细胞的促血管新生作用[J]中药药理与临床2007；23(2)
[14]杜力军,於兰,常琪,等.新工艺制备的葛根黄酮的药代动力学研究[J].中药药理与临床,1997,13(2)：19.
[15]朱燕辉,严奉祥黄芪甲苷及其生物学活性[J]现代生物医学进展2008V01.8 No.4-781。
[16]张红敏,谢春光,陈世伟.含药血清体外药理试验的评价[J].中国中西医结合杂志,2004,24(8)741-745.
[17]王喜军.中药血清药物化学的研究动态及发展趋势[J].中国中药杂志,2006,31(10)：789-792.
[18]吴楠,崔恒.XTT比色法在细胞活性检测中的应用[J]国外医学临床生物化学与检验学分册.1998;19(5)：204-6.
[19]李伟平,任浩洋,张宝阳,虞朝辉,厉有名VEGF在大鼠慢性酒精性肝损伤中的表达[J]世界华人消化杂志2006年6月28日14(18)：1766—1770
[20]董健伟,陈嘉峰酒精中毒后大鼠大脑皮质和海马的血管内皮生长因子变化及相关机制[J]中风与神经疾病杂志2007年10月第24卷第5期：558-560
[21]胡新贵,王国凤,薛丽霞,屈巧芳,申晓苯扎贝特对脐静脉内皮细胞内皮型一氧化氮合酶表达的影响及机制[J]中国动脉硬化杂志2009年第17卷第1期：14-18
[22]洪思佳,万建波,张庆文,张娥,胡光,刘倩青,李铭源一,王一涛三七总皂苷对人脐静脉内皮细胞的促血管新生作用[J]中药药理与临床2007；23(2)：28-31
[23]定天明,陈坚,张正行,张奕华生物体内一氧化氮的检测方法及其应用[J]药学进展2005年第29卷第5期：221-226
[24]车兆义,邹悦,宋清斌大鼠实验中几种常用的采血方法探讨[J]局解手术学杂志2008年第17卷第2期：84-85
[25]崔岚,祝德秋,陶达人葛根素药理作用研究进展[J]中国药师2004年第7卷第12期：924-927
[26]陈宁等 黄芪甲苷在大鼠体内的药代动力学和组织分布研究[J]生物加工过程2006年第4卷第3期：67-85.
[27]牛云飞,陈晓雯,李中南,刘玲消渴丸对胰岛β-细胞功能和胰岛素抵抗的影响[J]中国现代中药2006年第8卷第6期：26-29.
[28]袁昌杰,谭文红,付清平,兰鹏,陆玉雄消渴丸治疗90例2型糖尿病疗效观察[J]广东医学2008年12月第29卷第12期：2105-2108
[29]Wei Tan et al Chronic Alcohol Consumption Stimulates VEGF Expression, Tumor Angiogenesis and Progression of Melanoma in Mice [J]Cancer Biology & Therapy 2007; Vol.6 Issue 8
[30]Charalambos Vlachopoulos, Dorothea Tsekoura, Eleftherios Tsiamis, Demosthenes Panagiotakos and Christodoulos Stefanadis Effect of alcohol on endothelial function in healthy subjects Vasc Med 2003; 8; 263
1. Ignarro, L.J.;Buga, G. M.; Wood, K. S.:Byrns, R. E.;Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.Proc. Nail. Acad Sci. USA 84:9265-9269:(1987)
2. Palmer. R. M.J.;Ferrige. A. G.; Moncada. S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526; (1987)
3. Moncada, S.:Higgs, A. The L-arginine-nitric oxide pathway, N Engl J Med 329:2002-2012; (1993)
4. Arnold, W. P.; Mittal, C. K.; Katsuki, S.; Murad, F. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad Sci. USA 74:3203-3207; (1977)
5. Katsuki, S.; Arnold, W.; Mittal, C.; Murad, F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. Journal of cyclic nucleotide research 3:23-35; (1977)
6. Murad, F.; Mittal, C. K.; Arnold, W. P.; Katsuki, S.:Kimura, H. Guanylate cyclase:activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Advances in cyclic nucleotide research 9:145-158; (1978)
7. Murad, F.; Arnold, W. P.; Mittal, C. K.; Braughler, J. M. Properties and regulation of guanylate cyclase and some proposed functions for cyclic GMP. Advances in cyclic nucleotide research 11:175-204; (1979)
8. Furchgott, R. F.; Zawadzki, J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetycholine. Nature 288:373-376; (1980)
9. Murad, F. Cyclic guanosine monophosphare as a mediator of vasodiiation. J. Ciin. Invest.78:i-5:(1986)
10. Deguchi, T.; Yoshicka, M. L-Arginine identified as an endogenous activator for soluble guanylate cyclase from neuroblastoma cells.J. Biol Chem 257:10147-10151; (1982)
11. Knowles, R. G.:Palacios, M.; Palmer, R. M. J.:Moncada, S. Formation of nitric oxide from L-arginine in the central nervous system:A transduction mechanism for stimulation of the soluble guanylate cyclase. Proc. Natl. Acad Sci. USA 86:5159-5162; (1989)
12. Tannenbaum, S. R.; Fett, D.; Young, V. R.; Land, P. D.; Bruce, W. R. Nitrite and nitrate are formed by endogenous synthesis in the human intestine. Science 200:1487-1488:(1978)'
13. Stuehr, D. J.; Marletta, M. A. Mammalian nitrate biosynthesis:mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc. Natl. Acad Sci. USA 82:7738-7742; (1985)
14. Liu, Q.; S.S., G. Binding sites of nitric oxide synthases. Methods Enzymol 268:311-324; (1996)
15. Moncada, S.; Palmer, R. M. J.; Higgs, A. Nitric oxide:physiology, pathophysiology and pharmacology. Pharmacol Rev43:109-142;(1991)
16. Xia, H.; Bredt, D. S. Cloned and expressed nitric oxide synthase proteins. Methods in enzymology 268:427-436; (1996)
17. Marietta, M. A. Another activation switch for endothelial nitric oxide synthase:why does it have to be so complicated? Trends in biochemical sciences 26:519-521;(2001)
18. Bredt, D. S. Endogenous nitric oxide synthesis:biological functions and pathophysiology. Free radical research 31:577-596; (1999)
19. White, K. A.; Marletta, M. A. Nitric oxide synthase is a cytochrome P-450 type hemoprotein. Biochemistry 31:6627-6631; (1992)
20. Abu-Soud, H. M.; Yoho, L. L.; Stuehr, D.J. Caimoduiin controls neuronal nitric-oxide synthase by a dual mechanism. J Biol Chem.269:32047-32050; (1994)
21. Abu-Soud, H. M.; Stuehr, D. J. Nitric oxide synthases reveal a role for caimodulin in controlling electron transfer. Proc. Nail. Acad Sci. USA 90:10769-10772; (1993)
22. Dinerman, J. L.; Lowenstein, C. J.:Snyder, S. H. Molecular Mechanisms of Nitric Oxide Regulation Potential Relevance to Cardiovascular Disease. Circulation Research 73:217-222; (1993)
23. Bredt, D. S.; Snyder, S. H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad Sci. USA 87:682-685; (1990)
24. Stamler,J. S.; Singel, D.J.; Loscalzo,J. Biochemistry of Nitric oxide and its redox-activated forms. Science 258:1898-1902; (1992)
25. Ignarro, L.J. Haem-Dependent Activation of Guanylate Cyclase and Cyclic GMP Formation by Endogenous Nitric Oxide:A Unique Transduction Mechanism for Transcellular Signalling. Pharmacology & Toxicology 67:1-7; (1990)
26. Ignarro, L.J.; Adams,J. B.; Horwitz, P. M.:Wood, K. S. Activation of Soluble Guanylate cyclase by OHemoproteins Involves NO-Heme Exchange. J. Biol Chem 261:4997-5002; (1986)
27. Ignarro, L. J. Signal Transduction Mechanisms Nitric oxide signaling pathway and its targets 11 Involving Nitric Oxide. Biochemical Pharmacology 41:485-490; (1991)
28. Waldman, S. A.; Murad, F. Cyclic GMP Synthesis and Function. Pharmacol Rev 39:163-195; (1987)
29. Twort. C. H. C.;van Breemen. C. Cyclic Guanosine Monophosphate-Enhanced Sequestration of Ca2+ by Sarcoplasmic Reticulum in Vascular Smooth Muscle. Circulation Research 62:961-964; (1988)
30. Hathaway, D. R.:March. K. L.; Lash,J. A.:Adam, L. P.:Wilensky, R. L. Vascular Smooth Muscle:A review of the Molecular Basis of Contractility. Circulation 83:382-390; (1991)
31. Hathaway, D. R.; Konicki, M. V.; Coolican, S. A. Phosphorylation of Myosin Light Chain Kinase from Vascular Smooth Muscle by cAMP-and cGMP-dependent Protein Kinases. J Mol Cell Cardiol 17:841-850; (1985)
32. Sakuma, I.; Stuehr, D. J.; Gross, S. S.; Nathan, C.; Levi, R. Identification of arginine as a precursor of endotheliumderived relaxing factor. Proc. Natl. Acad Sci. USA 85:8664-8667; (1988)
33. Palmer, R. M. J.; Rees, D. D.; Ashton, D. S.; Moncada, S. L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Communs 153:1251-1256; (1988)
34. Radomski, M. W.; Palmer, R. M.J.; Moncada, S. An LArginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad Sci. USA 87:5193-5197; (1990)
35. Sase, K.; Michel,. T. Expression of Constitutive Endothelial Nitric Oxide Synthase in Human Blood Platelets. Life Sciences 57:2049-2055; (1995)
36. Salvemini, D.; De Nucci, G.; Gryglewski, R. J.; Vane, J. R. Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide like factor. Proc. Natl. Acad Sci. USA 86:6328-6332; (1989)
37. Radomski, M. W.; Palmer, R. M. J.; Moncada, S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br. J. Pharmac 92:181-187; (1987)
38. Bednar, M. M.:Gross, C. E.; Howard, D. B.; Russell, S. R.; Thomas, G. R. Nitric Oxide reverses aspririn antagonism of t-PA Thrombolysis in a rabbit model of thromboembolic stroke. Experimental Neurology 146:513-517; (1997)
39. Marletta, M. A.:Yoon, P. S.; lyengar, R.; Leaf, C. D.; Wishnok, J. S. Macrophage oxidation of L-arginine to nitrite and nitrate:nitric oxide is an intermediate. Biochemistry 27:8706-8711; (1988)
40. Yui, Y.; Hattori, R.; Kosuga, K.; Eizawa, H.; Hiki, K.; Ohkawa, S.; Ohnishi, K.:Terao, S.; Kawai, C. almodulinindependent nitric oxide synthase from rat polymorphonuclear neutrophils. J. Biol Chem 266:3369-3371; (1991)
41. Stuehr, D. J.; Marletta, M. A. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-gamma. The Journal of Immunology 139:518-525; (1987)
42. Ding, A. H.; Nathan, C. F.; Stuehr, D. J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. The Journal of Immunology 141:2407-2412; (1988)
43. Cho, H. J.; Xie, Q.-w. X.; Calaycay, J.; Mumford, R. A.; Swiderek, K. M.; Lee, T. D.; Nathan, C. F. Calmodulin is a subunit of nitric oxide synthase from macrophages. J. Exp. Med 176:599-604:(1992)
44. Welch, G.; Loscalzo, J. Nitric oxide and the Cardiovascular System. J. Card Surg 9:361-371; (1994)
45. Xie, Q.-w. X.;Cho, H. J.; Calaycay, J.; Mumford, R. A.; Swiderek, K. M.; Lee, T. D.; Ding, A.; Troso, T.; Nathan, C. F. Cloning and Characterization of inducible nitric oxide synthase from mouse macrophages.-Science 256:225-228; (1992)
46. Radomski, M. W.; Palmer, R. M. J.; Moncada, S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad Sci. USA 87:10043-10047; (1990)
47. Nathan, C. F.; Hibbs Jr, J. B. Role of Nitric Oxide synthesis in macrophage antimicrobial activity. Current Opinion in Immunology 3:65-70; (1991)
48. Stuehr, D. J.; Griffith, O. W. Mammalian nitric oxide synthases. Adv Enzymol Relat Areas Mol Biol 65:287-346;(1992)
49. Rodeberg, D. A.; Chaet, M. S.; Bass, R. C.; Arkovitz, M. S.; Garcia, V. F. Nitric Oxide:An Overview. The American Journal of Surgery 170:292-303; (1995)
50. Roerig, S.; Wolf, R.; Grisham, M. B. Nitric Oxide, Chronic Joint Inflammation, and Pain. In:Ignarro, L. J., ed.Nitric Oxide Biology and Pathobiology. San Diego:Academic Press; (2000):873-894.
51. Garthwaite, G.; Garthwaite, J. Differential dependence on Ca2+ of N-methyl-D-aspartate and quisqualate neurotoxicity in young rat hippocampal slices. Neuroscience Letters 97:316-322; (1989)
52. Lipton, S. A.;Choi, Y.-B.; Pan, Z.-H.; Lei, S. Z.; Chen, H.-S. V.; Sucher, N. J.; Loscalzo, J.; Singel, D. J.; Stamler, J. S. A redox based mechanism for the neuroprotective and Nitric oxide signaling pathway and its targets 12 neurodestructive effects of nitric oxide and related nitroso compounds. Nature 364:626-632; (1993)
53. Gillespie, J. S.;Liu, X.;Martin, W. The neurotransmitter of the non-adrenergic non-cholinergic inhibitory nerves to smooth muscle of the genital system. Elsevier Science Publishers BV;(1990)
54. Mersereau, W. A.;Hinchey, E. J. Effect of Gastric acidity on gastric ulceration induced by hemorrhage in the rat, utilizing a gastric chamber technique. Gastroenterology 64:1130-1135; (1973)
55. Ritchie, W. P.; Shearburn, E. W. Influence of isoproterenol and cholestyramine on acute gastric mucosal ulcerogenesis. Gastroenterology 73:62-65; (1977)
56. Whittle, B. J. R.; Boughton-Smith, N. K.; Moncada, S. Biosynthesis and role of th endothelium-derived vasodilator, nitric oxide, in the gastric mucosa. Ann NY Acad Sci 664:126-139; (1992)
57. Stark, M. E.; Szurszewski, J. H. Role of Nitric Oxide in Gastrointestinal and Hepatic Function and Disease. Gastroenterology 103:1928-1949;(1992)
58. Marsh. N.:Marsh. A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clinical and experimental pharmacology & physiology 27:313-319:(2000)
59. Zaher, C.; Goldberg, G. A.; Kadlubek, P. Estimating angina prevalence in a managed care population. The American journal of managed care 10:S339-346; (2004)
60. Leesar, M. A.; Stoddard, M. F.; Dawn, B.; Jasti, V. G.; Masden, R.; Bolli, R. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 103:2935-2941; (2001)
61. Lauretti, G. R.; Perez, M. V.; Reis, M. P.; Pereira, N. L. Double-blind evaluation of transdermal nitroglycerine as adjuvant to oral morphine for cancer pain management. Journal of clinical anesthesia 14:83-86; (2002)
62. Higa, M; Takasu, N.; Tamanaha, T.; Nakamura, K.; Shimabukuro, M.; Sasara, T.; Tawata, M. Nitroglycerin spray rapidly improves pain in a patient with chronic painful diabetic neuropathy. Diabet Med 21:1053-1054;(2004)
63. Lindsey, I.; Jones, O. M.; Cunningham, C.; Mortensen, N. J. Chronic anal fissure. The British journal of surgery 91:270-279; (2004)
64. Loehe, F.; Preissler, G.; Annecke, T.; Bittmann, I.; Jauch, K. W.; Messmer, K. Continuous infusion of nitroglycerin improves pulmonary graft function of nonheart-beating donor lungs. Transplantation 77:1803-1808;(2004)
65. Baxter, K.; Howden, B. O.; Jablonski, P. Heart preservation with celsior solution improved by the addition of nitroglycerine. Transplantation 71:1380-1384; (2001)
66. Yasuda, H.; Yamaya, M.; Nakayama, K.; Sasaki, T.; Ebihara, S.; Kanda, A.; Asada, M.; Inoue, D.; Suzuki, T.; Okazaki, T.; Takahashi, H.; Yoshida, M.;Kaneta, T.; Ishizawa, K.; Yamanda, S.; Tomita, N.; Yamasaki, M.; Kikuchi, A.; Kubo, H.; Sasaki, H. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage ⅢB/Ⅳ non-small-cell lung cancer. JClin Oncol 24:688-694; (2006)
67. Janero. D. R.. Bryan, N. S.; Saijo, F.; Dhawan. V.:Schwalb, D. J.:Warren, M. C.;Feelisch. M. Differential nitros(yl) ation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo. Proc. Natl. Acad Sci. USA 101:16958-16963:(2004)
68. Ahlner, J.; Andersson, R. G.; Torfgard, K.; Axelsson, K. L. Organic nitrate esters:clinical use and mechanisms of actions. Pharmacol Rev 43:351-423; (1991)
69. Fung, H. L. Biochemical mechanism of nitroglycerin action and tolerance:is this old mystery solved? Annual review of pharmacology and toxicology 44:67-85; (2004)
70. Chen, Z.; Zhang, J.; Stamler, J. S. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc. Natl. Acad Sci. USA 99:8306-8311; (2002)
71. Feelisch, M.; Noack, E. Nitric oxide (NO) formation from nitrovasodilators occurs independently of hemoglobin or non-heme iron. European journal of pharmacology 142:465-469; (1987)
72. Feelisch, M.; Kelm, M. Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochem Biophys Res Commun 180:286-293; (1991)
73. Russwurm, M.; Behrends, S.; Harteneck, C.; Koesling, D. Functional properties of a naturally occurring isoform of soluble guanylyl cyclase. The Biochemical journal 335 (Ptl):125-130; (1998)
74. Budworth, J.; Meillerais, S.; Charles, I.; Powell, K. Tissue distribution of the human soluble guanylate cyclases. Biochem Biophys Res Communs 263:696-701;(1999)
75. Mergia, E.; Russwurm, M.; Zoidl, G.; Koesling, D. Major occurrence of the new alpha2betal isoform of Osensitive guanylyl cyclase in brain. Cellular signaling 15:189-195; (2003)
76. Nimmegeers, S.; Sips, P.; Buys, E.; Brouckaert, P.; Van de Voorde, I. Functional role of the soluble guanylyl cyclase alpha(1) subunit in vascular smooth muscle relaxation. Cardiovascular research 76:149-159; (2007)
77. Lucas, K. A.; Pitari, G. M.; Kazerounian, S.; RuizNitric oxide signaling pathway and its targets 13 Stewart, I.; Park,J.; Schulz, S.; Chepenik, K. P.; Waldman, S. A. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52:375-414; (2000)
78. Biel, M.; Seeliger, M.; Pfeifer, A.; Kohler, K.; Gerstner, A.; Ludwig, A.; Jaissle, G.; Fauser, S.; Zrenner, E.; Hofmann, F. Selective loss of cone function in mice lacking the cyclic nucleotide-gated channel CNG3. Proc. Natl. Acad Sci. USA 96:7553-7557; (1999)
79. Boolell, M.; Allen, M. J.; Ballard, S. A.; Gepi-Attee, S.; Muirhead, G. J.:Naylor, A. M.; Osterloh,I.H.; Gingell, C. Sildenafil:an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. International journal of impotence research 8:47-52; (1996)
80. Humbert. P., Niroomand, F.; Fischer, G.:Mayer, B.; Koesling, D.:Hinsch, K. D.; Gausepohi, H.;Frank. R.; Schultz, G.; Bohme, E. Purification of soluble guanylyl cyclase from bovine lung by a new immunoaffinity chromatographic method. European journal of biochemistry/FEBS 190:273-278; (1990)
81. Lee, Y. C.; Martin, E.; Murad, F. Human recombinant soluble guanylyl cyclase:expression, purification, and regulation. Proc. Natl. Acad Sci. USA 97:10763-10768;(2000)
82. Conti, M. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Molecular endocrinology (Baltimore, Md 14:1317-1327; (2000)
83. Corbin, J. D.; Francis, S. H.; Webb, D. J. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 60:4-11; (2002)
84. Friebe, A.; Mergia, E.:Dangel, O.; Lange, A.; Koesling, D. Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc. Natl. Acad Sci. USA 104:7699-7704; (2007)
85. Mergia, E.; Friebe, A.; Dangel, O.; Russwurm, M.; Koesling, D. Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system. J. Clin. Invest.116:1731-1737; (2006)
86. Pyriochou, A.; Papapetropoulos, A. Soluble guanylyl cyclase:more secrets revealed. Cellular signalling 17:407-413; (2005)
87. Krumenacker, J. S.; Hyder, S. M.; Murad, F. Estradiol rapidly inhibits soluble guanylyl cyclase expression in rat uterus. Proc. Natl. Acad Sci. USA 98:717-722:(2001)
88. Kloss, S.; Srivastava, R.; Mulsch, A. Down-regulation of soluble guanylyl cyclase expression by cyclic AMP is mediated by mRNA-stabilizing protein HuR. Molecular pharmacology 65:1440-1451; (2004)
89. Papapetropoulos, A.; Marczin, N.; Mora, G.; Milici, A.; Murad, F.; Catravas, J. D. Regulation of vascular smooth muscle soluble guanylate cyclase activity, mRNA, and protein levels by cAMP-clcvating agents. Hypertension 26:696-704; (1995)
90. Papapetropoulos, A.; Abou-Mohamed, G.; Marczin, N.; Murad, F.; Caldwell, R. W.; Catravas, J. D. Downregulation of nitrovasodilator-induced cyclic GMP accumulation in cells exposed to endotoxin or interleukin-1 beta. Britishjournal of pharmacology 118:1359-1366;(1996)
91. Papapetropoulos, A.; Go, C. Y.:Murad, F.:Catravas, J. D. Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells. British journal of pharmacology 117:147-155; (1996)
92:Kimura. H.; Murad, F. Evidence for two different forms of guanylate cyclase in rat heart.J. Biol Chem 49:6910-6916;(1974)
93. Behrends, S.; I larteneck, C.; Schultz, G.; Koesling, D. A variant of the alpha 2 subunit of soluble guanylyl cyclase contains an insert homologous to a region within adenylyl cyciases and functions as a dominant negative protein.J. Biol Chem 270:21109-21113; (1995)
94. Behrends, S.; Vehse, K. The beta(2) subunit of soluble guanylyl cyclase contains a human-specific frameshift and is expressed in gastric carcinoma. Biochem Biophys Res Communs 271:64-69; (2000)
95. Chhajlani, V.; Frandberg, P. A.; Ahlner, J.; Axelsson, K. L.; Wikberg, J. E. Heterogeneity in human soluble guanylate cyclase due to alternative splicing. FEBS letters 290:157-158;(1991)
96. Okamoto, H. Molecular cloning of a novel variant of the rat soluble guanylate cyclase-beta2 suhunit. The international journal of biochemistry & cell biology 36:472-480; (2004)
97. Ritter, D.; Taylor, J. F.:Hoffmann, J. W.:Carnaghi, L.:Giddings, S. J.; Zakeri, H.:Kwok, P. Y. Alternative splicing for the alphal subunit of soluble guanylate cyclase. The Biochemical journal 346 Pt 3:811-816; (2000)
98. Evgenov, O. V.; Pacher, P.; Schmidt, P. M.; Hasko, G.; Schmidt, H. H.; Stasch, J. P. NO-independent stimulators and activators of soluble guanylate cyclase:discovery and therapeutic potential. Nat Rev Drug Discov 5:755-768; 2006)
99. Martin, E.; Lee, Y. C.; Murad, F. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components. Proc. Natl. Acad Sci. USA 98:12938-12942; (2001)
100. Bryan, N. S.; Calvert, J. W.; Elrod, J. W.; Gundewar, S.; Ji, S. Y.; Lefer, D. J. Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. Proc. Natl. Acad Sci. USA 104:19144-19149; (2007)
101. Bryan, N. S.; Fernandez, B. O.; Bauer, S. M.; Garcia-Saura, M. F.; Milsom, A. B.; Rassaf, T.; Maloney, R. E.; Nitric oxide signaling pathway and its targets 14 Bharti, A.; Rodriguez, J.; Feelisch, M. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol 1:290-297; (2005)
102. Zweier, J. L.; Wang, P.; Samouilov, A.; Kuppusamy, P. Enzyme-independent formation of nitric oxide in biological tissues. Nat Med 1:804-809; (1995)
103. Lundberg, J. O.; Weitzberg, E.; Lundberg, J. M.; Alving, K. Intragastric nitric oxide production in humans: measurements in expelled air. Gut 35:1543-1546:(1994)
104. Benjamin, N.; O'Driscoll, F.; Dougall, H.; Duncan, C.; Smith, L.; Golden, M.; McKenzie, H. Stomach NO synthesis. Nature 368:502; (1994)
105. Lundberg, J. O.; Weitzberg, E.; Gladwin, M. T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov; (2008)
106. Kleinbongard, P.; Dejam, A.; Lauer, T.; Rassaf, T.; Schindler, A.; Picker, O.; Scheeren, T.;Godecke, A.; Schrader, J.:Schulz, R.; Heusch, G.; Schaub, G. A.; Bryan, N. S.; Feelisch. M.; Kelm. M. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 35:790-796; (2003)
107. Gladwin, M. T.; Schechter, A. N.; Kim-Shapiro, D. B.; Patel, R. P.; Hogg, N.; Shiva, S.; Cannon, R. O.,3rd; Kelm, M.; Wink, D. A.; Espey, M. G.; Oldfield, E. H.; Pluta, R. M.; Freeman, B. A.; Lancaster, J. R., Jr.; Feelisch, M.; Lundberg, J. O. The emerging biology of the nitrite anion. Nat Chem Biol 1:308-314; (2005)
108. Bryan, N. S. Nitrite in nitric oxide biology:Cause or consequence? A systems-based review. Free Radic Biol Med
41:691-701; (2006)
[2]江清林,李延军,辛华.黄芪甲甙对胰岛素C肽分泌作用研究[J].黑龙江医药科学,1999,22(3)：24027.
[3]高学敏.中药学[M].北京：人民卫生出版社,2000：388.
[4]丁学屏.中西医结合治疗糖尿病[M].北京：人民卫生出版社,2004：1240143.
[5]沈忠明,李英,姜宏,等.降糖中药对α 0葡萄糖苷酶抑制作用的研究[J].中国生化药物杂志,2000,21(2)：69070.
[6]袁海波,沈忠明,殷建伟,等.五味子中α 0葡萄糖苷酶抑制剂对小鼠的降血糖作用[J].中国生化药物杂志,2002,23(3)：1120114.
[7]于健.葛根素治疗2型糖尿病患者胰岛素抵抗的临床研究[J].山东中医杂志,2001,20(12)：7270729.
[8]袁昌杰.消渴丸治疗90例2型糖尿病疗效观察[J].广东医学,2008,29(12)：210502106.
[9]吴继良.消渴丸治疗糖尿病疗效观察[J].实用中西医结合临床,2005,5(6)：18019.
[10]Potenza MA Gagliardi S Nacci C Carratu' MR Montagnani M Endothelial dysfunction in diabetes:from mechanisms to therapeutic targets Current medicinal chemistry,2009,16 (1):P.94-112
[11]雷世庸,胡娟娟中药血清药理学研究现状[J]现代医药卫生2009年第25卷第13期P2019
[12]王洪武,倪青,林兰中药含药血清的研究进展及其在中医学中的应用[J]北京中医药2008年9月第27卷第9期
[13]洪思佳,万建波,张庆文,张娥,胡光,刘倩青,李铭源一,王一涛三七总皂苷对人脐静脉内皮细胞的促血管新生作用[J]中药药理与临床2007；23(2)
[14]杜力军,於兰,常琪,等.新工艺制备的葛根黄酮的药代动力学研究[J].中药药理与临床,1997,13(2)：19.
[15]朱燕辉,严奉祥黄芪甲苷及其生物学活性[J]现代生物医学进展2008V01.8 No.4-781。
[16]张红敏,谢春光,陈世伟.含药血清体外药理试验的评价[J].中国中西医结合杂志,2004,24(8)741-745.
[17]王喜军.中药血清药物化学的研究动态及发展趋势[J].中国中药杂志,2006,31(10)：789-792.
[18]吴楠,崔恒.XTT比色法在细胞活性检测中的应用[J]国外医学临床生物化学与检验学分册.1998;19(5)：204-6.
[19]李伟平,任浩洋,张宝阳,虞朝辉,厉有名VEGF在大鼠慢性酒精性肝损伤中的表达[J]世界华人消化杂志2006年6月28日14(18)：1766—1770
[20]董健伟,陈嘉峰酒精中毒后大鼠大脑皮质和海马的血管内皮生长因子变化及相关机制[J]中风与神经疾病杂志2007年10月第24卷第5期：558-560
[21]胡新贵,王国凤,薛丽霞,屈巧芳,申晓苯扎贝特对脐静脉内皮细胞内皮型一氧化氮合酶表达的影响及机制[J]中国动脉硬化杂志2009年第17卷第1期：14-18
[22]洪思佳,万建波,张庆文,张娥,胡光,刘倩青,李铭源一,王一涛三七总皂苷对人脐静脉内皮细胞的促血管新生作用[J]中药药理与临床2007；23(2)：28-31
[23]定天明,陈坚,张正行,张奕华生物体内一氧化氮的检测方法及其应用[J]药学进展2005年第29卷第5期：221-226
[24]车兆义,邹悦,宋清斌大鼠实验中几种常用的采血方法探讨[J]局解手术学杂志2008年第17卷第2期：84-85
[25]崔岚,祝德秋,陶达人葛根素药理作用研究进展[J]中国药师2004年第7卷第12期：924-927
[26]陈宁等 黄芪甲苷在大鼠体内的药代动力学和组织分布研究[J]生物加工过程2006年第4卷第3期：67-85.
[27]牛云飞,陈晓雯,李中南,刘玲消渴丸对胰岛β-细胞功能和胰岛素抵抗的影响[J]中国现代中药2006年第8卷第6期：26-29.
[28]袁昌杰,谭文红,付清平,兰鹏,陆玉雄消渴丸治疗90例2型糖尿病疗效观察[J]广东医学2008年12月第29卷第12期：2105-2108
[29]Wei Tan et al Chronic Alcohol Consumption Stimulates VEGF Expression, Tumor Angiogenesis and Progression of Melanoma in Mice [J]Cancer Biology & Therapy 2007; Vol.6 Issue 8
[30]Charalambos Vlachopoulos, Dorothea Tsekoura, Eleftherios Tsiamis, Demosthenes Panagiotakos and Christodoulos Stefanadis Effect of alcohol on endothelial function in healthy subjects Vasc Med 2003; 8; 263
1. Ignarro, L.J.;Buga, G. M.; Wood, K. S.:Byrns, R. E.;Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.Proc. Nail. Acad Sci. USA 84:9265-9269:(1987)
2. Palmer. R. M.J.;Ferrige. A. G.; Moncada. S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526; (1987)
3. Moncada, S.:Higgs, A. The L-arginine-nitric oxide pathway, N Engl J Med 329:2002-2012; (1993)
4. Arnold, W. P.; Mittal, C. K.; Katsuki, S.; Murad, F. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad Sci. USA 74:3203-3207; (1977)
5. Katsuki, S.; Arnold, W.; Mittal, C.; Murad, F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. Journal of cyclic nucleotide research 3:23-35; (1977)
6. Murad, F.; Mittal, C. K.; Arnold, W. P.; Katsuki, S.:Kimura, H. Guanylate cyclase:activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Advances in cyclic nucleotide research 9:145-158; (1978)
7. Murad, F.; Arnold, W. P.; Mittal, C. K.; Braughler, J. M. Properties and regulation of guanylate cyclase and some proposed functions for cyclic GMP. Advances in cyclic nucleotide research 11:175-204; (1979)
8. Furchgott, R. F.; Zawadzki, J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetycholine. Nature 288:373-376; (1980)
9. Murad, F. Cyclic guanosine monophosphare as a mediator of vasodiiation. J. Ciin. Invest.78:i-5:(1986)
10. Deguchi, T.; Yoshicka, M. L-Arginine identified as an endogenous activator for soluble guanylate cyclase from neuroblastoma cells.J. Biol Chem 257:10147-10151; (1982)
11. Knowles, R. G.:Palacios, M.; Palmer, R. M. J.:Moncada, S. Formation of nitric oxide from L-arginine in the central nervous system:A transduction mechanism for stimulation of the soluble guanylate cyclase. Proc. Natl. Acad Sci. USA 86:5159-5162; (1989)
12. Tannenbaum, S. R.; Fett, D.; Young, V. R.; Land, P. D.; Bruce, W. R. Nitrite and nitrate are formed by endogenous synthesis in the human intestine. Science 200:1487-1488:(1978)'
13. Stuehr, D. J.; Marletta, M. A. Mammalian nitrate biosynthesis:mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc. Natl. Acad Sci. USA 82:7738-7742; (1985)
14. Liu, Q.; S.S., G. Binding sites of nitric oxide synthases. Methods Enzymol 268:311-324; (1996)
15. Moncada, S.; Palmer, R. M. J.; Higgs, A. Nitric oxide:physiology, pathophysiology and pharmacology. Pharmacol Rev43:109-142;(1991)
16. Xia, H.; Bredt, D. S. Cloned and expressed nitric oxide synthase proteins. Methods in enzymology 268:427-436; (1996)
17. Marietta, M. A. Another activation switch for endothelial nitric oxide synthase:why does it have to be so complicated? Trends in biochemical sciences 26:519-521;(2001)
18. Bredt, D. S. Endogenous nitric oxide synthesis:biological functions and pathophysiology. Free radical research 31:577-596; (1999)
19. White, K. A.; Marletta, M. A. Nitric oxide synthase is a cytochrome P-450 type hemoprotein. Biochemistry 31:6627-6631; (1992)
20. Abu-Soud, H. M.; Yoho, L. L.; Stuehr, D.J. Caimoduiin controls neuronal nitric-oxide synthase by a dual mechanism. J Biol Chem.269:32047-32050; (1994)
21. Abu-Soud, H. M.; Stuehr, D. J. Nitric oxide synthases reveal a role for caimodulin in controlling electron transfer. Proc. Nail. Acad Sci. USA 90:10769-10772; (1993)
22. Dinerman, J. L.; Lowenstein, C. J.:Snyder, S. H. Molecular Mechanisms of Nitric Oxide Regulation Potential Relevance to Cardiovascular Disease. Circulation Research 73:217-222; (1993)
23. Bredt, D. S.; Snyder, S. H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad Sci. USA 87:682-685; (1990)
24. Stamler,J. S.; Singel, D.J.; Loscalzo,J. Biochemistry of Nitric oxide and its redox-activated forms. Science 258:1898-1902; (1992)
25. Ignarro, L.J. Haem-Dependent Activation of Guanylate Cyclase and Cyclic GMP Formation by Endogenous Nitric Oxide:A Unique Transduction Mechanism for Transcellular Signalling. Pharmacology & Toxicology 67:1-7; (1990)
26. Ignarro, L.J.; Adams,J. B.; Horwitz, P. M.:Wood, K. S. Activation of Soluble Guanylate cyclase by OHemoproteins Involves NO-Heme Exchange. J. Biol Chem 261:4997-5002; (1986)
27. Ignarro, L. J. Signal Transduction Mechanisms Nitric oxide signaling pathway and its targets 11 Involving Nitric Oxide. Biochemical Pharmacology 41:485-490; (1991)
28. Waldman, S. A.; Murad, F. Cyclic GMP Synthesis and Function. Pharmacol Rev 39:163-195; (1987)
29. Twort. C. H. C.;van Breemen. C. Cyclic Guanosine Monophosphate-Enhanced Sequestration of Ca2+ by Sarcoplasmic Reticulum in Vascular Smooth Muscle. Circulation Research 62:961-964; (1988)
30. Hathaway, D. R.:March. K. L.; Lash,J. A.:Adam, L. P.:Wilensky, R. L. Vascular Smooth Muscle:A review of the Molecular Basis of Contractility. Circulation 83:382-390; (1991)
31. Hathaway, D. R.; Konicki, M. V.; Coolican, S. A. Phosphorylation of Myosin Light Chain Kinase from Vascular Smooth Muscle by cAMP-and cGMP-dependent Protein Kinases. J Mol Cell Cardiol 17:841-850; (1985)
32. Sakuma, I.; Stuehr, D. J.; Gross, S. S.; Nathan, C.; Levi, R. Identification of arginine as a precursor of endotheliumderived relaxing factor. Proc. Natl. Acad Sci. USA 85:8664-8667; (1988)
33. Palmer, R. M. J.; Rees, D. D.; Ashton, D. S.; Moncada, S. L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Communs 153:1251-1256; (1988)
34. Radomski, M. W.; Palmer, R. M.J.; Moncada, S. An LArginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad Sci. USA 87:5193-5197; (1990)
35. Sase, K.; Michel,. T. Expression of Constitutive Endothelial Nitric Oxide Synthase in Human Blood Platelets. Life Sciences 57:2049-2055; (1995)
36. Salvemini, D.; De Nucci, G.; Gryglewski, R. J.; Vane, J. R. Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide like factor. Proc. Natl. Acad Sci. USA 86:6328-6332; (1989)
37. Radomski, M. W.; Palmer, R. M. J.; Moncada, S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br. J. Pharmac 92:181-187; (1987)
38. Bednar, M. M.:Gross, C. E.; Howard, D. B.; Russell, S. R.; Thomas, G. R. Nitric Oxide reverses aspririn antagonism of t-PA Thrombolysis in a rabbit model of thromboembolic stroke. Experimental Neurology 146:513-517; (1997)
39. Marletta, M. A.:Yoon, P. S.; lyengar, R.; Leaf, C. D.; Wishnok, J. S. Macrophage oxidation of L-arginine to nitrite and nitrate:nitric oxide is an intermediate. Biochemistry 27:8706-8711; (1988)
40. Yui, Y.; Hattori, R.; Kosuga, K.; Eizawa, H.; Hiki, K.; Ohkawa, S.; Ohnishi, K.:Terao, S.; Kawai, C. almodulinindependent nitric oxide synthase from rat polymorphonuclear neutrophils. J. Biol Chem 266:3369-3371; (1991)
41. Stuehr, D. J.; Marletta, M. A. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-gamma. The Journal of Immunology 139:518-525; (1987)
42. Ding, A. H.; Nathan, C. F.; Stuehr, D. J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. The Journal of Immunology 141:2407-2412; (1988)
43. Cho, H. J.; Xie, Q.-w. X.; Calaycay, J.; Mumford, R. A.; Swiderek, K. M.; Lee, T. D.; Nathan, C. F. Calmodulin is a subunit of nitric oxide synthase from macrophages. J. Exp. Med 176:599-604:(1992)
44. Welch, G.; Loscalzo, J. Nitric oxide and the Cardiovascular System. J. Card Surg 9:361-371; (1994)
45. Xie, Q.-w. X.;Cho, H. J.; Calaycay, J.; Mumford, R. A.; Swiderek, K. M.; Lee, T. D.; Ding, A.; Troso, T.; Nathan, C. F. Cloning and Characterization of inducible nitric oxide synthase from mouse macrophages.-Science 256:225-228; (1992)
46. Radomski, M. W.; Palmer, R. M. J.; Moncada, S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad Sci. USA 87:10043-10047; (1990)
47. Nathan, C. F.; Hibbs Jr, J. B. Role of Nitric Oxide synthesis in macrophage antimicrobial activity. Current Opinion in Immunology 3:65-70; (1991)
48. Stuehr, D. J.; Griffith, O. W. Mammalian nitric oxide synthases. Adv Enzymol Relat Areas Mol Biol 65:287-346;(1992)
49. Rodeberg, D. A.; Chaet, M. S.; Bass, R. C.; Arkovitz, M. S.; Garcia, V. F. Nitric Oxide:An Overview. The American Journal of Surgery 170:292-303; (1995)
50. Roerig, S.; Wolf, R.; Grisham, M. B. Nitric Oxide, Chronic Joint Inflammation, and Pain. In:Ignarro, L. J., ed.Nitric Oxide Biology and Pathobiology. San Diego:Academic Press; (2000):873-894.
51. Garthwaite, G.; Garthwaite, J. Differential dependence on Ca2+ of N-methyl-D-aspartate and quisqualate neurotoxicity in young rat hippocampal slices. Neuroscience Letters 97:316-322; (1989)
52. Lipton, S. A.;Choi, Y.-B.; Pan, Z.-H.; Lei, S. Z.; Chen, H.-S. V.; Sucher, N. J.; Loscalzo, J.; Singel, D. J.; Stamler, J. S. A redox based mechanism for the neuroprotective and Nitric oxide signaling pathway and its targets 12 neurodestructive effects of nitric oxide and related nitroso compounds. Nature 364:626-632; (1993)
53. Gillespie, J. S.;Liu, X.;Martin, W. The neurotransmitter of the non-adrenergic non-cholinergic inhibitory nerves to smooth muscle of the genital system. Elsevier Science Publishers BV;(1990)
54. Mersereau, W. A.;Hinchey, E. J. Effect of Gastric acidity on gastric ulceration induced by hemorrhage in the rat, utilizing a gastric chamber technique. Gastroenterology 64:1130-1135; (1973)
55. Ritchie, W. P.; Shearburn, E. W. Influence of isoproterenol and cholestyramine on acute gastric mucosal ulcerogenesis. Gastroenterology 73:62-65; (1977)
56. Whittle, B. J. R.; Boughton-Smith, N. K.; Moncada, S. Biosynthesis and role of th endothelium-derived vasodilator, nitric oxide, in the gastric mucosa. Ann NY Acad Sci 664:126-139; (1992)
57. Stark, M. E.; Szurszewski, J. H. Role of Nitric Oxide in Gastrointestinal and Hepatic Function and Disease. Gastroenterology 103:1928-1949;(1992)
58. Marsh. N.:Marsh. A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clinical and experimental pharmacology & physiology 27:313-319:(2000)
59. Zaher, C.; Goldberg, G. A.; Kadlubek, P. Estimating angina prevalence in a managed care population. The American journal of managed care 10:S339-346; (2004)
60. Leesar, M. A.; Stoddard, M. F.; Dawn, B.; Jasti, V. G.; Masden, R.; Bolli, R. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 103:2935-2941; (2001)
61. Lauretti, G. R.; Perez, M. V.; Reis, M. P.; Pereira, N. L. Double-blind evaluation of transdermal nitroglycerine as adjuvant to oral morphine for cancer pain management. Journal of clinical anesthesia 14:83-86; (2002)
62. Higa, M; Takasu, N.; Tamanaha, T.; Nakamura, K.; Shimabukuro, M.; Sasara, T.; Tawata, M. Nitroglycerin spray rapidly improves pain in a patient with chronic painful diabetic neuropathy. Diabet Med 21:1053-1054;(2004)
63. Lindsey, I.; Jones, O. M.; Cunningham, C.; Mortensen, N. J. Chronic anal fissure. The British journal of surgery 91:270-279; (2004)
64. Loehe, F.; Preissler, G.; Annecke, T.; Bittmann, I.; Jauch, K. W.; Messmer, K. Continuous infusion of nitroglycerin improves pulmonary graft function of nonheart-beating donor lungs. Transplantation 77:1803-1808;(2004)
65. Baxter, K.; Howden, B. O.; Jablonski, P. Heart preservation with celsior solution improved by the addition of nitroglycerine. Transplantation 71:1380-1384; (2001)
66. Yasuda, H.; Yamaya, M.; Nakayama, K.; Sasaki, T.; Ebihara, S.; Kanda, A.; Asada, M.; Inoue, D.; Suzuki, T.; Okazaki, T.; Takahashi, H.; Yoshida, M.;Kaneta, T.; Ishizawa, K.; Yamanda, S.; Tomita, N.; Yamasaki, M.; Kikuchi, A.; Kubo, H.; Sasaki, H. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage ⅢB/Ⅳ non-small-cell lung cancer. JClin Oncol 24:688-694; (2006)
67. Janero. D. R.. Bryan, N. S.; Saijo, F.; Dhawan. V.:Schwalb, D. J.:Warren, M. C.;Feelisch. M. Differential nitros(yl) ation of blood and tissue constituents during glyceryl trinitrate biotransformation in vivo. Proc. Natl. Acad Sci. USA 101:16958-16963:(2004)
68. Ahlner, J.; Andersson, R. G.; Torfgard, K.; Axelsson, K. L. Organic nitrate esters:clinical use and mechanisms of actions. Pharmacol Rev 43:351-423; (1991)
69. Fung, H. L. Biochemical mechanism of nitroglycerin action and tolerance:is this old mystery solved? Annual review of pharmacology and toxicology 44:67-85; (2004)
70. Chen, Z.; Zhang, J.; Stamler, J. S. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc. Natl. Acad Sci. USA 99:8306-8311; (2002)
71. Feelisch, M.; Noack, E. Nitric oxide (NO) formation from nitrovasodilators occurs independently of hemoglobin or non-heme iron. European journal of pharmacology 142:465-469; (1987)
72. Feelisch, M.; Kelm, M. Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochem Biophys Res Commun 180:286-293; (1991)
73. Russwurm, M.; Behrends, S.; Harteneck, C.; Koesling, D. Functional properties of a naturally occurring isoform of soluble guanylyl cyclase. The Biochemical journal 335 (Ptl):125-130; (1998)
74. Budworth, J.; Meillerais, S.; Charles, I.; Powell, K. Tissue distribution of the human soluble guanylate cyclases. Biochem Biophys Res Communs 263:696-701;(1999)
75. Mergia, E.; Russwurm, M.; Zoidl, G.; Koesling, D. Major occurrence of the new alpha2betal isoform of Osensitive guanylyl cyclase in brain. Cellular signaling 15:189-195; (2003)
76. Nimmegeers, S.; Sips, P.; Buys, E.; Brouckaert, P.; Van de Voorde, I. Functional role of the soluble guanylyl cyclase alpha(1) subunit in vascular smooth muscle relaxation. Cardiovascular research 76:149-159; (2007)
77. Lucas, K. A.; Pitari, G. M.; Kazerounian, S.; RuizNitric oxide signaling pathway and its targets 13 Stewart, I.; Park,J.; Schulz, S.; Chepenik, K. P.; Waldman, S. A. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52:375-414; (2000)
78. Biel, M.; Seeliger, M.; Pfeifer, A.; Kohler, K.; Gerstner, A.; Ludwig, A.; Jaissle, G.; Fauser, S.; Zrenner, E.; Hofmann, F. Selective loss of cone function in mice lacking the cyclic nucleotide-gated channel CNG3. Proc. Natl. Acad Sci. USA 96:7553-7557; (1999)
79. Boolell, M.; Allen, M. J.; Ballard, S. A.; Gepi-Attee, S.; Muirhead, G. J.:Naylor, A. M.; Osterloh,I.H.; Gingell, C. Sildenafil:an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. International journal of impotence research 8:47-52; (1996)
80. Humbert. P., Niroomand, F.; Fischer, G.:Mayer, B.; Koesling, D.:Hinsch, K. D.; Gausepohi, H.;Frank. R.; Schultz, G.; Bohme, E. Purification of soluble guanylyl cyclase from bovine lung by a new immunoaffinity chromatographic method. European journal of biochemistry/FEBS 190:273-278; (1990)
81. Lee, Y. C.; Martin, E.; Murad, F. Human recombinant soluble guanylyl cyclase:expression, purification, and regulation. Proc. Natl. Acad Sci. USA 97:10763-10768;(2000)
82. Conti, M. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Molecular endocrinology (Baltimore, Md 14:1317-1327; (2000)
83. Corbin, J. D.; Francis, S. H.; Webb, D. J. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 60:4-11; (2002)
84. Friebe, A.; Mergia, E.:Dangel, O.; Lange, A.; Koesling, D. Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc. Natl. Acad Sci. USA 104:7699-7704; (2007)
85. Mergia, E.; Friebe, A.; Dangel, O.; Russwurm, M.; Koesling, D. Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system. J. Clin. Invest.116:1731-1737; (2006)
86. Pyriochou, A.; Papapetropoulos, A. Soluble guanylyl cyclase:more secrets revealed. Cellular signalling 17:407-413; (2005)
87. Krumenacker, J. S.; Hyder, S. M.; Murad, F. Estradiol rapidly inhibits soluble guanylyl cyclase expression in rat uterus. Proc. Natl. Acad Sci. USA 98:717-722:(2001)
88. Kloss, S.; Srivastava, R.; Mulsch, A. Down-regulation of soluble guanylyl cyclase expression by cyclic AMP is mediated by mRNA-stabilizing protein HuR. Molecular pharmacology 65:1440-1451; (2004)
89. Papapetropoulos, A.; Marczin, N.; Mora, G.; Milici, A.; Murad, F.; Catravas, J. D. Regulation of vascular smooth muscle soluble guanylate cyclase activity, mRNA, and protein levels by cAMP-clcvating agents. Hypertension 26:696-704; (1995)
90. Papapetropoulos, A.; Abou-Mohamed, G.; Marczin, N.; Murad, F.; Caldwell, R. W.; Catravas, J. D. Downregulation of nitrovasodilator-induced cyclic GMP accumulation in cells exposed to endotoxin or interleukin-1 beta. Britishjournal of pharmacology 118:1359-1366;(1996)
91. Papapetropoulos, A.; Go, C. Y.:Murad, F.:Catravas, J. D. Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells. British journal of pharmacology 117:147-155; (1996)
92:Kimura. H.; Murad, F. Evidence for two different forms of guanylate cyclase in rat heart.J. Biol Chem 49:6910-6916;(1974)
93. Behrends, S.; I larteneck, C.; Schultz, G.; Koesling, D. A variant of the alpha 2 subunit of soluble guanylyl cyclase contains an insert homologous to a region within adenylyl cyciases and functions as a dominant negative protein.J. Biol Chem 270:21109-21113; (1995)
94. Behrends, S.; Vehse, K. The beta(2) subunit of soluble guanylyl cyclase contains a human-specific frameshift and is expressed in gastric carcinoma. Biochem Biophys Res Communs 271:64-69; (2000)
95. Chhajlani, V.; Frandberg, P. A.; Ahlner, J.; Axelsson, K. L.; Wikberg, J. E. Heterogeneity in human soluble guanylate cyclase due to alternative splicing. FEBS letters 290:157-158;(1991)
96. Okamoto, H. Molecular cloning of a novel variant of the rat soluble guanylate cyclase-beta2 suhunit. The international journal of biochemistry & cell biology 36:472-480; (2004)
97. Ritter, D.; Taylor, J. F.:Hoffmann, J. W.:Carnaghi, L.:Giddings, S. J.; Zakeri, H.:Kwok, P. Y. Alternative splicing for the alphal subunit of soluble guanylate cyclase. The Biochemical journal 346 Pt 3:811-816; (2000)
98. Evgenov, O. V.; Pacher, P.; Schmidt, P. M.; Hasko, G.; Schmidt, H. H.; Stasch, J. P. NO-independent stimulators and activators of soluble guanylate cyclase:discovery and therapeutic potential. Nat Rev Drug Discov 5:755-768; 2006)
99. Martin, E.; Lee, Y. C.; Murad, F. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components. Proc. Natl. Acad Sci. USA 98:12938-12942; (2001)
100. Bryan, N. S.; Calvert, J. W.; Elrod, J. W.; Gundewar, S.; Ji, S. Y.; Lefer, D. J. Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. Proc. Natl. Acad Sci. USA 104:19144-19149; (2007)
101. Bryan, N. S.; Fernandez, B. O.; Bauer, S. M.; Garcia-Saura, M. F.; Milsom, A. B.; Rassaf, T.; Maloney, R. E.; Nitric oxide signaling pathway and its targets 14 Bharti, A.; Rodriguez, J.; Feelisch, M. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol 1:290-297; (2005)
102. Zweier, J. L.; Wang, P.; Samouilov, A.; Kuppusamy, P. Enzyme-independent formation of nitric oxide in biological tissues. Nat Med 1:804-809; (1995)
103. Lundberg, J. O.; Weitzberg, E.; Lundberg, J. M.; Alving, K. Intragastric nitric oxide production in humans: measurements in expelled air. Gut 35:1543-1546:(1994)
104. Benjamin, N.; O'Driscoll, F.; Dougall, H.; Duncan, C.; Smith, L.; Golden, M.; McKenzie, H. Stomach NO synthesis. Nature 368:502; (1994)
105. Lundberg, J. O.; Weitzberg, E.; Gladwin, M. T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov; (2008)
106. Kleinbongard, P.; Dejam, A.; Lauer, T.; Rassaf, T.; Schindler, A.; Picker, O.; Scheeren, T.;Godecke, A.; Schrader, J.:Schulz, R.; Heusch, G.; Schaub, G. A.; Bryan, N. S.; Feelisch. M.; Kelm. M. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 35:790-796; (2003)
107. Gladwin, M. T.; Schechter, A. N.; Kim-Shapiro, D. B.; Patel, R. P.; Hogg, N.; Shiva, S.; Cannon, R. O.,3rd; Kelm, M.; Wink, D. A.; Espey, M. G.; Oldfield, E. H.; Pluta, R. M.; Freeman, B. A.; Lancaster, J. R., Jr.; Feelisch, M.; Lundberg, J. O. The emerging biology of the nitrite anion. Nat Chem Biol 1:308-314; (2005)
108. Bryan, N. S. Nitrite in nitric oxide biology:Cause or consequence? A systems-based review. Free Radic Biol Med
41:691-701; (2006)